Aurinia Pharmaceuticals (AUPH) Depreciation & Amortization (CF) (2024 - 2026)

Aurinia Pharmaceuticals (AUPH) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $4.8 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 0.82% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.4 million (changed 0.23% YoY) and the FY2025 annual result came in at $19.4 million, changed 0.02% from the prior year.
• Depreciation & Amortization (CF) slipped to $4.8 million in Q1 2026, from $4.9 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $5.3 million in Q3 2023 to a low of -$6.1 million in Q4 2023.
• A 5-year average of $2.6 million and a median of $4.8 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) slumped 223.16% — and 2024, when it jumped 576.01%.
• Tracing AUPH's Depreciation & Amortization (CF) over 5 years: stood at -$1.9 million in 2022, then tumbled by 223.16% to -$6.1 million in 2023, then jumped by 179.73% to $4.9 million in 2024, then rose by 0.04% to $4.9 million in 2025, then retreated by 0.99% to $4.8 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $4.8 million (Q1 2026), $4.9 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.